Source: Cardiovascular diabetology. Unidade: FM
Subjects: DOENÇAS CARDIOVASCULARES, ARTERIOSCLEROSE, DISLIPIDEMIAS, LIPÍDEOS, LIPOPROTEÍNAS HDL, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, PEROXISSOMOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FRUCHART, Jean-Charles et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovascular diabetology, v. 18, 2019Tradução . . Disponível em: https://doi.org/10.1186/s12933-019-0864-7. Acesso em: 11 nov. 2024.APA
Fruchart, J. -C., Santos Filho, R. D. dos, Aguilar-salinas, C., Aikawa, M., Rasadi, K. A., Amarenco, P., et al. (2019). The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovascular diabetology, 18. doi:10.1186/s12933-019-0864-7NLM
Fruchart J-C, Santos Filho RD dos, Aguilar-salinas C, Aikawa M, Rasadi KA, Amarenco P, Barter PJ, Ceska R, Corsini A, Despres J-P. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation [Internet]. Cardiovascular diabetology. 2019 ; 18[citado 2024 nov. 11 ] Available from: https://doi.org/10.1186/s12933-019-0864-7Vancouver
Fruchart J-C, Santos Filho RD dos, Aguilar-salinas C, Aikawa M, Rasadi KA, Amarenco P, Barter PJ, Ceska R, Corsini A, Despres J-P. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation [Internet]. Cardiovascular diabetology. 2019 ; 18[citado 2024 nov. 11 ] Available from: https://doi.org/10.1186/s12933-019-0864-7
